The ligand specificities of sites binding tritium-labeled arginine vasopressin (3H-AVP) were investigated in membrane preparations of rat anterior pituitary gland and liver. Labeled AVP interacted with high-affinity, low-capacity binding sites in liver as well as in pituitary membrane fractions. Binding displacement studies showed that AVP was a potent ligand for liver (K1 = 0.23 nM) and pituitary (K1 = 0.4 nM) receptors. Oxytocin and the antidiuretic (V2) agonist dDAVP had low affinities (K1 > 10 nM) both for liver and pituitary binding sites. The pressor (V1) antagonist d(CH2)5Tyr(Me)AVP was equipotent with AVP in liver membranes, but was 1,000-fold less potent on pituitary receptors. Another V1 antagonist, dPenTyr(Me)AVP, displaced 3H-AVP with K1 values of 3 and 8 nM from pituitary and liver receptors, respectively. These data are in reasonable agreement with recent studies of the in vitro biological activities of the analogs tested, and suggest that the ligand specificity of rat pituitary AVP receptors is distinct from those of previously characterized V1, V2 and oxytocin binding sites in the rat.

Keywords:
V1 antagonists, Oxytocin, dDAVP
This content is only available via PDF.
© 1984 S. Karger AG, Basel
1984
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.